FDA Approves Capivasertib with Abiraterone and Prednisone for PTEN-deficient Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer By Ogkologos - July 15, 2026 130 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR News digest – smoking ban, HPV and prostate cancer, genetic testing... July 18, 2020 After Spine Tumor, Teacher Goes On Mission To Serenade Hospital Patients... June 24, 2019 FDA Approves Margetuximab for Metastatic HER2-positive Breast Cancer January 4, 2021 EMA Recommends Granting a Marketing Authorisation for Lutetium (177lu) Chloride August 4, 2022 Load more HOT NEWS Improving research with registered reports After Struggling With Chronic Illnesses Most of Her Life, This Author... ESMO Targeted Anticancer Therapies Congress 2025, Paris, France, 3-5 March Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for...
